FDA Drug Safety Communication: FDA warns of serious skin reactions with the anti-seizure drug Onfi (clobazam) and has approved label changes Safety Announcement[removed]The U.S. Food and Drug Administration (FDA) is - Open NAND Flash Interface Working Group - Document - PDFSEARCH.IO

First Page	Meta Content
	FDA Drug Safety Communication: FDA warns of serious skin reactions with the anti-seizure drug Onfi (clobazam) and has approved label changes Safety Announcement[removed]The U.S. Food and Drug Administration (FDA) is Add to Reading List Open Document File Size: 60,50 KB Share Result on Facebook Company Lundbeck / IMS Health / Lennox / / Country United States / / IndustryTerm retail / / MedicalCondition Stevens-Johnson syndrome / seizure / seizures / epilepsy / hypersensitivity / hives / muscle cramps / hallucinations / rash / skin rash / blindness / toxic epidermal necrolysis / / MedicalTreatment alternative therapy / concomitant therapy / alternate therapy / antibiotics / / Organization FDA / U.S. Food and Drug Administration / / Product sulfasalazine / Onfi / / PublishedMedium the Medication Guide / / SocialTag Organochlorides Benzodiazepines Clobazam Lactams Stevens–Johnson syndrome Toxic epidermal necrolysis Open NAND Flash Interface Working Group Epilepsy Urticaria Health

FDA Drug Safety Communication: FDA warns of serious skin reactions with the anti-seizure drug Onfi (clobazam) and has approved label changes Safety Announcement[removed]The U.S. Food and Drug Administration (FDA) is Add to Reading List